Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Wednesday's top analyst calls include AMD, Amazon.com, Celgene, Comerica, Fortinet, Gilead Sciences, Lennar, Netflix, Voya and Wayfair.
While these were not the five biggest absolute losers of the week, of the active stocks, these all issued news or had news that took place and pushed the stocks down.
These companies are well along in clinical trials and some are close to presenting Phase 3 results. Sticking with industry leaders always makes sense in a very volatile sector.
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Celgene Corp. (NASDAQ: CELG) sank in Monday's session after providing a business update that was largely in line with analyst expectations.
Chris Lange The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
Baird has maintained Outperform ratings on three top companies that have reported outstanding numbers and had positive catalysts. All three could be solid additions to aggressive growth portfolios for 2016.
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
The top analyst calls for Thursday include Celgene, DigitalGlobe, Micron Technology, Paychex and Bed Bath & Beyond.
Wednesday’s top analyst upgrades, downgrades and initiations includes Apple, Celgene, General Electric, Micron Technology, Nike, ONEOK, Darden Restaurants and Delphi Automotive.
The November 30 short interest data have been compared with the previous report, and short interest was mixed in these selected stocks for this settlement date.
A new Jefferies research report features some solid new growth stock calls that make good sense for people looking to perhaps replace stocks that underperformed this past year.
A Merrill Lynch report focuses on five top stocks that underperformed this year but that could outperform in 2016.
24/7 Wall St. has reviewed the short interest data on the top biotech companies.
